Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness

References

• Pearlstein T, Stone AB. Premenstrual syndrome. Psychiatr. Clin. North Am.21(3), 577–590 (1998).
   PubMed Web of Science ®Google Scholar
• Borenstein JE, Dean BB, Endicott J et al. Health and economic impact of the premenstrual syndrome. J. Report. Med.48(7), 515–524 (2003).
   PubMed Web of Science ®Google Scholar
• Pearlstein T, Joliat MJ, Brown EB, Miner CM. Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment. Am. J. Obstet. Gynecol.188, 887–895 (2003).
   PubMed Web of Science ®Google Scholar
• Sternfeld B, Swindle R, Chawla A, Long S. Severity of premenstrual symptoms in a health maintenance organization population. Obstet. Gynecol.99(6), 1014–1024 (2002).
   PubMed Web of Science ®Google Scholar
• Mortola JF, Girton L, Yen SS. Depressive episodes in premenstrual syndrome. Am. J. Obstet. Gynecol.161(6, Pt 1), 1682–1687 (1989).
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. Premenstrual syndrome. ACOG Pract. Bull.15, 1–9 (2000).
   Google Scholar
• Ginsburg KA, Dinsay R. Premenstrual syndrome. In: Practical Strategies in Obstetrics and Gynecology. Ransom SB (Ed.). WB Saunders Company, PA, USA, 684–694 (2000).
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). DC, USA, 771–774 (Text Revision) (2000).
   Google Scholar
• Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology Suppl. 3, 1–23 (2003).
   Google Scholar
• World Health Organization. The ICD-10 Classification of Mental, Behavioral and Development Disorders, 10th Revision. World Health Organization, Geneva, Switzerland (1987).
   Google Scholar
• Rapkin AJ, Mikacich JA. Premenstrual syndrome in adolescents: diagnosis and treatment. Pediatr. Endocrinol. Rev.3(Suppl. 1), 132–137 (2006).
   PubMedGoogle Scholar
• Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology28(Suppl. 3), 25–37 (2003).
   PubMed Web of Science ®Google Scholar
• Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology28(Suppl. 3), 55–99 (2003).
   Web of Science ®Google Scholar
• Van der Akker OBA et al. Genetic and environmental variation in menstrual cycle: histories of two British twin samples. Acta Genet. Med. Gemellol. (Roma)36, 541–548 (1987).
   Google Scholar
• Kendler KS et al. Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psychol. Med.22, 85–100 (1992).
   PubMedGoogle Scholar
• Warner P. The relationship between perimenstrual depressive mood and depressive illness. J. Affect. Disord.23, 9–23 (1991).
   PubMed Web of Science ®Google Scholar
• Endicott J: The menstrual cycle and mood disorders. J. Affect. Disord.29(2–3), 193–200 (1993).
   PubMed Web of Science ®Google Scholar
• Rapkin AJ, Edelmuth E, Chang LC et al. Whole-blood serotonin in premenstrual syndrome. Obstet. Gynecol.70(4), 533–537 (1987).
   PubMed Web of Science ®Google Scholar
• Clayton AH, Keller AE, Leslie C et al. Exploratory study of premenstrual symptoms and serotonin variability. Arch. Womens Ment. Health9(1), 51–57 (2006).
   PubMed Web of Science ®Google Scholar
• Rasgon N, Mcguire M, Tanavoli S et al. Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertil. Steril.73(1), 144–149 (2000).
   PubMed Web of Science ®Google Scholar
• Rasgon N, Serra M, Biggio G et al. Neuroactive steroid-serotonergic interaction: responses to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Eur. J. Endocrinol.14525–14533 (2001).
   Google Scholar
• Jovanovic H, Cerin A, Karlsson P et al. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res.148(2–3), 185–193 (2006).
   PubMed Web of Science ®Google Scholar
• Wyatt KM, Dimmock PW, O’Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev.4, CD001396 (2002).
   Google Scholar
• Freeman EW, Rickels K, Sondheimer SJ et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch. Gen. Psychiatry56(10), 932–939 (1999).
   PubMed Web of Science ®Google Scholar
• Backstrom T, Andersson A, Andree L et al. Pathogenesis in menstrual cycle-linked disorders. Ann. NY Acad. Sci.1007, 42–53 (2003).
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Nieman LK, Danaceau MA et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med.338(4), 256–257 (1998).
   PubMed Web of Science ®Google Scholar
• Majewska MD, Harrison NL, Schwartz RD et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science232(4753), 1004–1007 (1986).
   PubMed Web of Science ®Google Scholar
• Rapkin Aj, Morgan M, Goldman L et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol.90(5), 709–714 (1997).
   PubMed Web of Science ®Google Scholar
• Wang M, Seippel L, Purdy RH, Bãckström T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 α-pregnane-3,20-dione and 3 α-hydroxy-5 α-pregnan-20-one. J. Clin. Endocrinol. Metab.81(3), 1076–1082 (1996).
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Purdy RH, Moore PH Jr et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J. Clin. Endocrinol. Metab.79(5), 1256–1260 (1994).
   PubMed Web of Science ®Google Scholar
• Smith SS. Withdrawal properties of a neuroactive steroid: implications for GABAA receptor gene regulation in the brain and anxiety behavior. Steroids67(6), 519–528 (2002).
   PubMed Web of Science ®Google Scholar
• Sundström Poromaa I, Smith S, Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch. Womens Ment. Health6(1), 23–41 (2003).
   PubMedGoogle Scholar
• Thys-Jacobs S, McMahon D, Bilesikian JP. Cyclical changes in calcium metabolism across the menstrual cycle in women with premenstrual dysphoric disorder. J. Clin. Endocrinol. Metab.92(8), 2952–2959 (2007).
   PubMed Web of Science ®Google Scholar
• Dimmock PW, Wyatt KM, Jones PW et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet356, 1131–1136 (2000).
   PubMed Web of Science ®Google Scholar
• Steiner M, Hirshberg AL, Bergeron R et al. Lueal phase dosing with paroxetine controlled release (Cr) in the treatment of premenstrual dyshoric disorder. Am. J. Obstet. Gynecol.193(2), 352–360 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen LS, Miner C, Brown EW et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet. Gynecol.100(3), 435–444 (2002).
   PubMed Web of Science ®Google Scholar
• Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J. Clin. Psychiatry58(9), 399–402 (1997).
   PubMed Web of Science ®Google Scholar
• Sundström-Poromaa I, Bixo M, Björn I et al. Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. J. Psychosom. Obstet. Gynaecol.21(4), 205–211 (2000).
   PubMed Web of Science ®Google Scholar
• Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs62(13), 1869–1885 (2002).
   PubMed Web of Science ®Google Scholar
• Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J. Clin. Psychiatry.55, 332–335 (1994).
   PubMed Web of Science ®Google Scholar
• Shah NR, Jones JB, Aperi J et al. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet. Gynecol.111(5), 1175–1182 (2008).
   PubMed Web of Science ®Google Scholar
• Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: Predictors of improvement and deterioration. Am. J. Obstet. Gynecol.189(6), 1523–1530 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan H, Furniss H, Spona J et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil. Steril.72(1), 115–120 (1999).
   PubMed Web of Science ®Google Scholar
• Rapkin AJ, Biggio G, Concas A. Oral contraceptives and neuroactive steroids. Pharmacol. Biochem. Behav.84(4), 628–634 (2006).
   PubMed Web of Science ®Google Scholar
• Muhn P, Krattemacher R, Beier S et al. Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception51(2), 99–110 (1995).
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Scow RD, Preece C. Hormonal withdrawal symptoms in oral contraceptive users. Obstet. Gynecol.95(2), 261–266 (2000).
   PubMed Web of Science ®Google Scholar
• Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet. Gynecol.106(3), 492–501 (2005).
   PubMed Web of Science ®Google Scholar
• Pearlstein TB, Bachmann GA, Zacur HA et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception72(6), 414–421 (2005).
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Heartwell S, Edwards S et al. Oral contraceptive discontinuation: do side effects matter? Am. J. Obstet. Gynecol.196(4), 412–416; discussion 412.e6 (2007).
   PubMed Web of Science ®Google Scholar
• Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotrophin-releasing hormone agonist and estrogen/progestin. J. Clin. Endocrinol. Metab.71, 252A–252F (1991).
   Web of Science ®Google Scholar
• Wyatt KM, Dimmock PW, Ismail KM et al. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG111(6), 585–593 (2004).
   PubMed Web of Science ®Google Scholar
• Haywood A, Slade P, King H. Assessing the assessment measures for menstrual cycle symptoms: a guide for researchers and clinicians. J. Psychosom. Res.52(4), 223–237 (2002).
   PubMed Web of Science ®Google Scholar
• Feuerstein M, Shaw WS. Measurement properties of the calendar of premenstrual experience in patients with premenstrual syndrome. J. Report. Med.47(4), 279–289 (2002).
   PubMed Web of Science ®Google Scholar
• Moos RH. The development of a menstrual distress questionnaire. Psychosom. Med.30(6), 853–867 (1968).
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W. Daily Record of severity of problems (DRSP): reliability and validity. Arch. Womens Ment. Health9(1), 41–49 (2006).
   PubMed Web of Science ®Google Scholar
• Borenstein JE, Dean BB, Yonkers KA, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. J. Obstet. Gynecol.109(5), 1068–1075 (2007).
   Google Scholar
• Ware JE Jr. SF-36 health survey update. Spine25(24), 3130–3139 (2000).
   PubMed Web of Science ®Google Scholar
• Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch. Gen. Psychiatry33(9), 1111–1115 (1976).
   PubMed Web of Science ®Google Scholar
• Wallenstein GV, Blaisdell-Gross B, Gajria K et al. Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool. J. Womens Health (Larchmt)17(3), 439–450 (2008).
   PubMed Web of Science ®Google Scholar
• Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and auality of life. Annu. Rev. Public Health22, 91–113 (2001).
   PubMed Web of Science ®Google Scholar
• Pearlstein TB, Halbreich U, Batzar ED et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J. Clin. Psychiatry61, 101–109 (2000).
   PubMed Web of Science ®Google Scholar
• Rappaport MH. Quality-of-life impairment in depressive and anxiety disorders. Am. J. Psychiatry162(6), 1171–1118 (2005).
   Google Scholar
• Nisar N, Zehra N, Haider G et al. Frequency, intensity and impact of premenstrual syndrome in medical students. J. Coll. Physicians Surg. Pak.18(8), 481–484 (2008).
   PubMed Web of Science ®Google Scholar
• Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J. Womens Health Gend. Based Med.8(8), 1043–1052 (1999).
   PubMed Web of Science ®Google Scholar
• Robinson RL, Swindle RW. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. J. Womens Health Gend. Based Med.9(7), 757–768 (2000).
   PubMed Web of Science ®Google Scholar
• Freeman EW. Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder. Pharmacoeconomics23(5), 433–444 (2005).
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol. Med.32, 119–132 (2002).
   PubMed Web of Science ®Google Scholar
• Dean BB, Borenstein JE. A prospective assessment investigating the relationship between work productivity and impairment with premenstrual syndrome. J. Occup. Environ. Med.46(7), 649–656 (2004).
   PubMed Web of Science ®Google Scholar
• Borenstein J, Chiou CF, Dean B et al. Estimating direct and indirect costs of premenstrual syndrome. J. Occup. Environ. Med.47(1), 26–33 (2005).
   PubMed Web of Science ®Google Scholar
• Dean BB, Borenstein JE, Knight K, Yonkers K. Evaluating the criteria used for identification of PMS. J. Womens Health (Larchmt)15(5), 546–555 (2006).
   PubMedGoogle Scholar
• Chawla A, Swindle R, Long S et al. Premenstrual dysphoric disorder: is there an economic burden of illness? Med. Care40(11), 1101–1112 (2002).
   PubMed Web of Science ®Google Scholar
• Borenstein JE, Dean BB, Leifke E et al. Differences in symptom scores and health outcomes in premenstrual syndrome. J. Womens Health (Larchmt)16(8), 1139–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Barnard K, Frayne SM, Skinner KM, Sullivan LM. Health status among women with menstrual symptoms. J. Womens Health (Larchmt)12(9), 911–919 (2003).
   PubMed Web of Science ®Google Scholar
• Pearlstein T, Steiner M. Premenstrual dysphoric disorder: burden of illness and treatment update. J. Psychiatry Neurosci.33(4), 291–301 (2008).
   PubMed Web of Science ®Google Scholar
• The Global Burden of Disease. Murray CJL, Lopez AD (Eds). Harvard University Press, MA, USA (1966).
   Google Scholar
• Yang M, Wallenstein G, Hagan M et al. Burden of premenstrual dysphoric disorder on health-related quality of life. J. Womens Health (Larchmt)17(1), 113–121 (2008).
   PubMed Web of Science ®Google Scholar